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ABSTRACT
The tobacco market has been transformed by the arrival of e-cigarettes
and array of alternative nicotine delivery systems (ANDS). Public health
has struggled to cope with these changes and clear divisions are appar-
ent, but less is known about the tobacco industry (TI) response. This ﬁrst
empirical study to examine TI and independent ANDS companies’ busi-
ness strategies ﬁlls this gap. Primary data were collected through 28 elite
interviews with senior/inﬂuential TI and independent stakeholders, trian-
gulated with a documentary analysis of company reports, investor ana-
lyses, market research, and consultation responses (1022 documents).
A deliberately emic analysis shows that tobacco multinationals were
initially disconcerted by ANDS, but logic provided by the ﬁduciary
imperative is enabling them to turn a potential threat into proﬁtable
opportunities. Interviewees argue market changes played to their
strengths: customer links, expertise in nicotine, and enormous ﬁnancial
resources. This enabled portfolio diversiﬁcation in which combustible
and ANDS coexist; providing potential to develop robust scientiﬁc and
regulatory positions and hope of retrieving corporate reputations. The
principal threat for major tobacco players comes from the independent
sector, which is prepared and able to satisfy bespoke consumer needs.
Multinationals by contrast need to turn ANDS into a genuinely mass-
market product appealing to its global customers. They are making
progress. Given the continued buoyancy of the combustibles market,
they have extensive resources to continue their eﬀorts. Disruptive inno-
vations are not unique to tobacco control. Equivalent technological
solutions – with concomitant business opportunities − are emerging in
obesity and alcohol ﬁelds with implications for public health.
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Introduction
The last ﬁve years have seen major innovations in the tobacco and nicotine market (Bauld, Angus,
de Andrade, & Ford, 2016). The arrival of the electronic cigarette (e-cigarette) and multiple other
alternative nicotine delivery systems (ANDS) means that the traditional cigarette (or ‘combustible’)
has been joined by a portfolio of products spanning new categories: ﬁrst-generation e-cigarettes
(closed system cig-a-likes, which replicate the look and feel of combustibles); vapours, tanks, and
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mods (VTMs) with open reﬁllable systems; tobacco-heated products; and licensed medicinal
products (Bauld et al., 2016). While public health has struggled to cope with these sudden changes
(Kamat & Van Dyke, 2017; Russell, Wainwright, & Tilson, 2018; Sim & Mackie, 2014), following Milton
Friedman’s dictum, ‘The business of business is business’ (Ridgers, 2012), the tobacco industry (TI)
has responded with clear and productive focus (Branston & Sweanor, 2015). There has been much
speculation about the TI’s business intentions regarding these developments but little empirical
evidence.
This study with ANDS industry stakeholders from both tobacco companies and independent
producers (with no ties to the TI) ﬁlls this gap. Grounded in critical debates concerning the
relationship between corporate proﬁt making and public health, it problematises tobacco control’s
polarised positions on whether ANDS are ‘good’ or ‘bad’ for public health (de Andrade, Spotswood,
Hastings, Angus, & Angelova, 2017). It does this by critiquing an emic analysis of business strategies
(from the perspective of interviewees) being deployed in the e-cigarette/ANDS market by both
tobacco multinationals and independent companies.
The decision to interview TI representatives was a diﬃcult one for the research team (see below)
given the well-documented deceit of these companies and the obvious conﬂict of interest between
the business corporation’s quest for proﬁts and harm to public health caused by smoking. Bakan
(2004) argues that this pursuit of self-interest is nothing short of psychopathic, and like their human
equivalents, this ruthlessness is hidden beneath a veneer of superﬁcial charm (Hastings, 2012).
Many researchers have warned against the power and inﬂuence of the tobacco multinationals
and, for example, for the need to focus eﬀorts on controlling them through government action
(e.g. see de Beyer & Brigden, 2003) or to guard against them manipulating the ‘deﬁnition of the
parameters of the problem and the elaboration of solutions’ (Breton, Richard, & Gagnon, 2007,
p. 360). Through this lens, we are reminded of the industry’s unhealthy tactics including claims of
‘junk science’ to fulﬁl political agendas, withholding data adverse to corporate products, using
information in misleading ways, corporate funded research, funding researchers and institutions to
conduct ‘independent’ studies at arm’s length, threatening to sue (or actually suing), inﬁltrating
scientiﬁc groups, creation of doubt to prevent litigation or regulation when it suits, diverting
attention from harmful products, dividing and conquering uniﬁed groups by feeding controversies,
and promoting corporate social responsibility (CSR; Freudenberg, 2014; Grougiou, Dedoulis, &
Leventis, 2016; Moodie et al., 2013; Oreskes & Conway, 2010; Wiist, 2010). In this context, seeking
the TI’s opinions seems ill-advised at best, and Article 5.3 of the World Health Organization
Framework Convention on Tobacco Control (WHO FCTC) – which deliberately isolates public health
from industry inﬂuence (WHO, 2003) – is a sensible consensus to adopt.
However, the arrival of ANDS has disrupted this unanimity. The dilemmas researchers face in
attempting to traverse the boundaries of such a politicised ﬁeld as tobacco control have
become more complicated through a public health community divided over ‘two sides’ of an
e-cigarette ‘argument’ that ‘have produced a global divide on policy strategies’ (Green, Fielding,
& Brownson, 2018, p. 189). It is increasingly diﬃcult to adopt a neutral stance when conducting
and trying to publish e-cigarette research: papers are rejected for not being grounded in a pro-
or anti-tobacco harm reduction position (often inﬂuenced by reviewers’ and journals’ views on
the subject), and there is an a priori assumption, based on their deceitful past, that the TI’s
strategies are questionable and that ANDS could be their newest hoodwink (de Andrade et al.,
2017; Gornall, 2015).
Other established tobacco control positions have also been disrupted by ANDS. Jacobson,
Wasserman, and Raube’s (1993; cited in Breton et al., 2007, p. 360) observation that ‘in the eyes
of legislators and individuals, the industry has truly lost the debate on scientiﬁc evidence’ seems
less convincing in an era of harm reduction and disruptive new product development (Hasselbalch,
2016). The monolithic conception of ‘Big Tobacco’ as a homogeneous entity has been undermined
by the arrival of independent companies with no TI connections promoting ANDS, and there has
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continued to be ‘an ironic convergence in the tobacco industry and [parts of the] tobacco control
community positions’ (Mair & Kierans, 2007, p. 104).
At the same time, public health cannot ignore the ‘commercial determinants of ill health’
(Hastings, 2012) and that tobacco-use continues to be the most hazardous of these. Studying
the disease vector is, therefore, vitally important, and interviewing industry representatives is,
arguably, a crucial part of this. Furthermore, if public health does not do this direct research,
others will, and an important opportunity will be lost. As Hastings (2012, p. 3) argues: ‘Public health
has to demand a place at the macroeconomic table; it has to contribute to the debate about where
corporate capitalism is going and ensure that the public health implications of business decision
making are fully appreciated’.
Materials and methods
The original funding proposal did not include primary data collection with representatives from the
TI, with applicants citing Article 5.3 of the WHO FCTC. A conditional oﬀer response from Cancer
Research UK’s Tobacco Advisory Group Committee noted ‘that the proposal would beneﬁt from
speaking to people responsible for marketing the products themselves, or creating their marketing
strategies’ and ‘felt the applicants could use intermediaries to achieve this if they felt this was
necessary’. After careful consideration, the research team decided to conduct the interviews
themselves.
An emic analysis was conducted using both primary data from interviews and a documentary
analysis of the business strategies being deployed in the ANDS market by tobacco and indepen-
dent companies. This qualitative approach was an attempt to understand and explore companies’
motivations, intentions, and strategies from the subject’s perspective – using insider accounts
(Headland, Pike, & Harris, 1990). Thoughts and actions were collected and critiqued in terms of the
actors’ (both independent stakeholders’ and the TI’s) culturally and historically bound self-
understanding (Morris, Leung, Ames, & Lickel, 1999).
Primary data were collected through a unique data-set of elite interviews (Berry, 2002; Welch,
Marschan-Piekkari, Penttinen, & Tahvanainen, 2002). The elite interviewee is
an informant . . . who occupies a senior or middle management position; has functional responsibility in an
area which enjoys high status in accordance with corporate values; has considerable industry experience and
frequently also long tenure with the company; possesses a broad network of personal relationships; and has
considerable international exposure. (Welch et al., 2002, p. 613)
Interview data were triangulated against a documentary analysis of more than 1000 documents
to understand what views senior stakeholders were expressing, to whom (e.g. investors, media, or
retailers) and why. Hasselbach (2016) investigated stakeholders’ framing of the European Union
(EU) policy debate on e-cigarettes regulation; however, the authors could not locate any empirical
studies adopting a business perspective.
Primary interview data collection
The lead researcher collecting, and principally analysing, the primary data was a female academic
researcher and qualiﬁed investigative journalist with extensive interviewing experience. She is part
of a group that has critically analysed e-cigarette marketing and industry involvement in public
health policy (de Andrade, Hastings, & Angus, 2013; Hastings, de Andrade, & Moodie, 2012). This
remains a highly contested area for public health research, and the study purpose was not to pitch
a pro- or anti-harm reduction perspective but to explore business strategies from the viewpoints of
business stakeholders. As far as possible, the interviewees’ own words are used.
A purposive sampling strategy was used to identify appropriate individuals and gatekeepers
among TI stakeholders and independents. To facilitate access, the researcher attended two
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conference(s)/summit(s) where TI and non-TI stakeholders were present. The purpose of atten-
dance was not to gather data but to meet gatekeepers and potential interviewees and gain further
understanding of business strategies. Snowball sampling was used to access additional senior and
inﬂuential interviewees, through introductions or referrals, until suﬃcient people had been inter-
viewed. Interviewing continued until saturation was reached.
Despite a predictable reluctance to talk about such a controversial topic, it was possible to
achieve this because the TI is so monolithic: just ﬁve transnational tobacco companies control 84%
of the global cigarette market (Campaign for Tobacco-Free Kids, 2016). Twenty-eight individuals
were interviewed, split into TI (interviewee has or is working for/with TI as employee/consultant/
analyst, n = 13) and non-TI interviewees (stakeholders in the e-cigarette sector who are indepen-
dent from the TI including manufacturers/distributors/retailers/advocates, n = 15; see de Andrade
et al., 2017, for interview settings and duration). TI interviewees were or had been associated with
three of the big ﬁve tobacco multinationals and/or other major tobacco companies as employees,
consultants, or analysts. This partial coverage may be a source of bias. Independent respondents
stipulated that they had no ties with the TI (ﬁnancial or otherwise) and as such might have had
diﬀerent interests and motivations. The researchers have no personal or professional relationshipto
any interviewees, but some had previously attended the same tobacco control meetings/confer-
ences and/or were aware of their research.
An open-ended interview style drew on the aims of the study, which were to examine tobacco
companies’ business approaches, targeting strategies, positions on harm reduction, and marketing
plans, and was shaped by interviewees’ responses. The topic is extremely contentious and subject
to a great diversity of opinion, so the interviewer sought to maintain a neutral position. Interviews
were conducted between April 2015 and November 2016 either face to face or by telephone.
Participants received a project information sheet and informed consent form and had the oppor-
tunity to ask questions about the study. Interviews were recorded on digital audio ﬁles, given an
anonymous ﬁlename and professionally transcribed. These transcriptions were subsequently
checked by the research team. Transcript storage was on secure, password-protected servers and
encrypted.
Ethical approval was granted by the School of Health in Social Science Research Ethics
Committee at the University of Edinburgh.
Documentary analysis
It can be diﬃcult to access data in most corporate sectors that are likely to give an insight into
a company’s deﬁned business objectives, scrutiny of its operating environments, and coordination
of its long-term bearing. ANDS stakeholders operate in a competitive environment and are likely to
withhold long-term plans for commercial sensitivity reasons in order to seek advantage over rival
companies. Documentation likely to contain business strategies are company reports, analyses
prepared for investors, press releases, newspaper articles, and third-party market research reports.
Databases of internal TI documents have been researched previously (e.g. see Peeters & Gilmore,
2013, 2015) and were excluded from this study. A comprehensive literature search captured
publicly available English-language data from multiple sources: databases, websites, and print
sources (see Appendix 1 in Supplement for details). Search terms for the databases included the
following: ‘electronic cigarette’, ‘e-cigarette’, ‘vaping’, ‘vapo(u)r device’, ‘business’, ‘strategy’, ‘fore-
cast’, ‘analysis’, and brand names. We note that TI companies are generally publicly listed so there
are many reports available, but many of the companies producing ANDS are smaller, and not all are
publicly listed. As annual reports were only a small part of our documentary search, this is not
a signiﬁcant source of bias. An initial search was conducted between November 2015 and
February 2016 resulting in 1022 uploaded to NVivo for coding. Additional ad hoc searches were
conducted for triangulation with primary data until February 2017.
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A further data source for triangulation was data extraction of TI and non-TI responses to the
Scottish Government’s 2014–2015 consultation on electronic cigarettes and tobacco control
(Scottish Government, 2015). From 170 responses, 14 were identiﬁed as relevant to this study
(linked to ANDS companies; not members of the public/public health; see Appendix 2 in
Supplement). Government consultation responses can also provide insights into how companies
operate (Ulucanlar, Fooks, Hatchard, & Gilmore, 2014).
Data analysis and synthesis
The constant comparison method of qualitative analysis was employed to compare new data with
previously collected data across three data-sets using a team of researchers to ensure reliability,
validity, and minimise bias (see Appendix 3 in Supplement for the coding strategy). Informed by
inductive techniques of grounded theory, open coding was used by two researchers for each data-
set to identify ﬁrst-level concepts followed by thematic coding with a clear focus on business
strategies. Coding was checked by a third researcher. Analytic meetings were held throughout data
collection and analysis to discuss emergent themes, deﬁnitions, resolve discrepancies, and reﬂect
on data interpretations as they arose. These informed ongoing interviews conducted by the lead
researcher so that interviewees could respond to emergent ﬁndings in an iterative way (see
Appendix 4 in Supplement for the codes used in the data analysis).
Upon completion of primary interview data collection, a thematic network was created by the lead
researcher ‘to explore the understanding of an issue or the signiﬁcation of an idea [TI and non-TI business
strategies], rather than to reconcile conﬂicting deﬁnitions of a problem’ (Attride-Stirling, 2001, p. 387; see
Appendix 5 in Supplement for the thematic network). This guided triangulation with documentary
sources, substantiated by further ad hoc searches in stage two databases conducted from March 2016
until February 2017 and by market reports/documents sent to the lead researcher during data collection.
As this is a rapidly evolving ﬁeld, this approach ensured ﬁndings reﬂected latest developments.
Given the study’s commercial focus, and its emic approach, ﬁnal synthesis of the TI’s response to
ANDS employed the classic business framework of SWOT analysis, widely recognised in the
strategic planning literature to map internal strengths (S) and weaknesses (W) against external
opportunities (O) and threats (T); (Helms & Nixon, 2010).
Methodological limitations of this study include the research team’s expertise in researching the
impact of marketing and business on society. The ﬁrst three authors are known in the ﬁeld of tobacco
control and public health for their critical views on industry tactics. Their backgrounds may have
inﬂuenced the study even though the intention was to maintain a neutral position. This potential bias
was minimised by the ability to recruit TI stakeholders for primary interview data collection despite
previous public criticisms and including a fourth researcher in the team from an unrelated discipline to
assist with data analysis. The unstructured nature of interviews could also be viewed as a limitation,
though it is also a strength as it allows for ﬂexibility of responses in a constantly evolving competitive
market with stakeholders expressing divergent views. The project was not resourced to do further
documentary data searches (e.g. other UK consultations) for longer time periods.
Results
Several TI respondents noted that the tobacco business is driven by the ﬁduciary imperative: the
need to prioritise shareholder returns above all other concerns (Bakan, 2004). This means that the
massive changes in the market brought about by the arrival of ANDS are ‘not complicated’, as a TI
representative noted, but actually ‘quite easy’ to address because ‘every activity going on is there
to please the shareholder . . . as long as shareholder value is threatened, [the TI’s] gonna continue
to protect it’ (Int6). A further TI spokesperson added that the challenge of change is, therefore,
reduced to questions about how ‘to grow our market share’ and ‘margins per thousand’, and so
turn a possible threat into ‘quite the business opportunity’ (Int15). See our analysis in Figure 1.
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Strengths
According to industry, the TI’s long-established position in the market brings four important
strengths. First, it has enormous logistical capacity in production, distribution, and marketing.
One TI representative commented on how the ‘sheer size’ of their distribution channels can
facilitate growth in this new market as ‘major companies have great distribution networks’ (Int9).
This, according to a TI competitor, gives tobacco companies a ‘big edge’ (Int15). British American
Tobacco (BAT)-owned Nicoventures echoed this in the documentary analysis by saying that
‘suppliers remain keen to harness the traditional grocery channels to move their products’
(Hegarty, 2015, p. 52).
Independent stakeholders reﬂected on how this provides an opportunity for e-cigarettes to ‘be
connected directly into their [TI] network of distribution, their network of sales’ (Int13). One
explained that the TI
followed into the vapour space with their various cig-a-like products that are sold through the same marketing
channels of distribution that they already control, which is the convenience stores and the supermarkets and
the gas stations. Wherever you ﬁnd tobacco products, that’s where you ﬁnd Big Tobacco’s vapour products.
(Int19)
This, according to a diﬀerent independent advocate, means they have the capacity to scale up and
distribute these new products – to ‘mass manufacture them’ and then ‘eventually get to the point
where you can be proﬁtable’ (Int1).
The TI’s second strength is its customer base, which an industry insider described as a vital asset
when ‘business strategy is driven by consumer needs’ (Int11). Int4, a TI executive, said that ‘the
people that are using e-cigarettes are the people that used to use cigarettes. So the consumers are
the same, at least at the moment’. The interviewee went on to explain that it is, therefore, ‘an
absolute natural notion that you would go and start producing e-cigarettes when your consumers
have left your product category and gone to another product category’ – ‘that’s just basic common
Strengths Opportunities
Logistical capacity
Customer base
Nicotine expertise
Money
Diversification
Sustainable business model
Scientific respectability
A role in regulation
Reputational gain
Weaknesses Threats
Slow transitions in ‘lower- and middle-
income countries’
(Historically) bureaucratic: ANDS came as 
a surprise
Poor reputation
Other tobacco multinationals
Independent companies
Figure 1. SWOT analysis of the tobacco industry’s response to alternative nicotine delivery systems.
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sense’ (int4). Given that the global pool of smokers is about a billion strong, this was framed as
a major advantage for industry.
The TI’s third strength, again from the perspective of tobacco representatives, is its extensive
technical knowledge about all things nicotine related. One TI executive said that industry is in
a ‘better positioned to deliver on the science, to deliver on a product that meets the needs of
consumers’ as it has ‘got folks that have done nothing but study tobacco their entire careers’ (Int8).
Finally, given the continuing proﬁtability of combustibles, the industry has ﬁnancial resources
needed to innovate and adapt. Protecting the cigarette market is, therefore, ‘a near term necessity’,
according to one TI interviewee, as ‘the stock price and investor interest’ comes from maintaining
‘traditional products . . . combustible cigarette products, for as long as possible’ (Int9). Another TI
interviewee added, ‘all that investment and that innovation costs a lot of money that is funded
today by proﬁts from the combustible brand’ (Int8). Commenting on ‘the realities of the current
combustible market’ and the fact that ‘cigarettes are obviously a proﬁtable product’, the same
interviewee said that ‘simply stopping making those products doesn’t put us in a position to
deliver innovation and to get through these costly [regulatory] pathways that are now in front of all
of us’ (Int8). A diﬀerent TI spokesperson further explained that tobacco companies may see
traditional tobacco as a ‘sunset business’, but they ‘can’t just stop producing cigarettes, because
cigarettes – the income from cigarettes – is the boiler-plate for investment’ (Int6).
Thus, combustibles will ‘remain the mainstay of BAT’s commercial delivery for a long time’,
because they provide ‘the funding required to develop less-harmful next-generation products’
(Tuinstra, 2015, p. 24) a sector in which it aims ‘to achieve global leadership . . . by 2020’ (Rossel,
2016, p. 18). Similarly, Philip Morris International (PMI) notes that ‘while combustible cigarettes are
likely to remain at the core of PMI’s business for years, the company has been investing heavily in
next-generation products’ with ‘tobacco harm-reduction objectives and commercial objectives
starting to align’ (Tuinstra, 2015, p. 16). The company aims ‘to lead the combustible product
category, leveraging the great strengths of [its] existing business’ and, like BAT, ‘become the
undisputed leader of the Reduced-Risk Product category’ (PMI, 2016a, p. 1). It feels ‘very well
positioned to deliver on both growth engines’ (PMI, 2016b, p. 2)1.
Weaknesses
Analysts note, however, that transitions will be slow in ‘lower and middle-income countries’, which
‘are home to 80% of the global smoking population’ (TechNavio, 2016). One TI interviewee
explained that ‘emerging markets will be a solid combustible cigarette consuming base for
many, many years to come’ (Int9). They went on to clarify that ‘cigarettes are extremely cheap’,
so ‘these are much more price driven decisions’ for consumers: ‘it’s really hard for me to imagine
a bunch of very low-income individuals . . . wanting to switch, or even caring, if they can aﬀord
cigarettes’ (Int9). The ‘economics of demand’ (Int9) present ‘a dilemma’, which a TI competitor
explained as follows: ‘the price point to get into [ANDS] . . . is still high cos you’ve got [to buy]
a device, so how d’you make that economical for the [developing] world?’ (Int4).
The TI’s established position brings two signiﬁcant further weaknesses, according to indepen-
dents and TI representatives. First, like many large businesses, tobacco companies had become
bureaucratic and set in their ways. ANDS took them by surprise, as this independent interviewee
explains:
[ANDS] got on the market without asking permission . . . so quickly that they weren’t able to be killed oﬀ . . .
[The TI] did not start this business. This business was foisted on them by entrepreneurs out of China, picked up
by entrepreneurs elsewhere – they reacted, they didn’t create it. (Int1)
A TI spokesperson also spoke about how the TI ‘sat back and watched’ the ‘completely consumer
driven revolution’ and only belatedly ‘jumped in the game’ (Int8) when, according to one inde-
pendent, they became ‘aware that this nascent interloper could cause a threat’ (Int13). A TI
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executive added that ‘it took some time’ for industry to recognise ‘a space that might become
quite big, going forward’ even though ‘vape shops [were] popping up’ and e-cigarettes were
becoming a ‘cult thing’ (Int10).
An independent interviewee said the TI had a realisation that ‘every time somebody switches
from smoking to vaping [tobacco companies] lose a customer’, so this meant that they needed ‘to
be in the game’, to ‘take a place in this market’, and ‘make money from that’ (Int25). TI competitors
added that this was a ‘big signal to companies’ that ‘adult smokers are looking for alternatives’
(Int15) as ‘consumers don’t wanna be dying from the products that they’re consuming’ (Int9). As
Int8 put it, the TI’s ‘licence to operate is threatened if people view . . . nothing but malicious intent’.
This points to the TI’s second great weakness: a reputation for ruthless business practice. Several
independents noted that ‘nobody trusts the tobacco industry’ (Int19). The lethal characteristics of
cigarettes combined with past duplicity have made it a pariah (Christoﬁdes, Chapman, &
Dominello, 1999; Hastings, 2012).
Opportunities
Turning to the external environment, ANDS present the TI with opportunities in ﬁve areas. First, they
enable diversiﬁcation. For 150 years, the industry has been dependent on one increasingly embattled
oﬀering: combustible tobacco. TI executives said that ANDS oﬀer the chance to move to a much
stronger ‘portfolio’ businessmodel (Int4). One TI interviewee said that this approach is ‘really important’
as smokers are not a ‘homogenous group’, so ‘there is never gonna be a silver bullet which just works all
across all of the diﬀerent markets in terms of what every single adult smoker is looking for’ (Int15). They
highlighted the need for ‘a range of products to satisfy consumer needs’ (Int15), echoing views in
tobacco trade press about ‘catering to all consumer needs’ (Rossel, 2016, p. 18).
Thus, for BAT, ‘diﬀerentiated products’ with ‘brand strength’ are part of the ‘commercial
attractiveness’ of next-generation productions (Wheaton, 2015). It has ‘developed a portfolio of
products spanning three categories: tobacco heated products (THP), e-cigarettes and licensed
medicinal products’ (Rossel, 2016, p. 18). Similarly, JTI has ‘expanded’ its ‘product portfolio by
entering in[to] new categories’ through, for example, the acquisition of the independent company
E-Lites to ‘complement’ the company’s ‘heat-not-burn oﬀering’ (McCoy, 2015). Meanwhile, PMI
notes that ‘a comprehensive portfolio approach to the category and [its] platforms are designed to
address a range of diﬀerent audiences and usage occasions’ (PMI, 2016a, p. 11).
ANDS also oﬀer long-term strategic opportunities, presenting a ‘sustainable business model’
according to a TI executive (Int9). They added that at present, ‘companies aren’t particularly
rewarded or acknowledged for these alternative products that they’re investing in, either through
R&D or acquisition’, but these are viewed ‘as necessary for longer-term sustainability’ (Int9). The TI
is investing in these products because ‘that’s where [it] see[s] demand is headed, even if it’s taking
a little bit longer to catch up, potentially, than originally thought’ (Int9). A TI competitor agreed
that ‘it’s all about investment. This is not about putting the products on the shelf, intending to start
to make millions or billions from it overnight’ (Int4). A diﬀerent TI spokesperson added that what
‘we’ll see over the next ﬁve years is a ﬂip, where the margins are much much greater than even our
most proﬁtable cigarette brand’ (Int8).
This future proﬁtability will be strongly inﬂuenced by taxation policy, with heavy tax on
combustibles making ANDS more commercially attractive. According to an independent intervie-
wee, the TI has worked out that ‘you’re looking at a much higher level of proﬁt from e-cigs’ as
‘there is no punitive taxation’ on them (Int12). They added,
for once . . . the retailers, the distributors and the tobacco companies are the biggest stakeholders, as is the
case in most other businesses . . . Now, it doesn’t take a great intellect to see that if you retain more of the
selling price . . . you’re going to be more proﬁtable [and] if they’re gonna be more proﬁtable ﬂogging e-cigs
and the environment is made easier for them to do that, then why wouldn’t they? (Int12)
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ANDS also oﬀer the TI an opportunity to own safety and science. The ANDS market has had quality
control problems, which the TI says it can resolve. It can impose ‘quality standards’ and ‘tighten up’
design to eliminate problems such as ‘exploding batteries’ (Int15). More profoundly, it sees itself as
‘leading the ﬁeld of the science’ (Int18), citing ‘the large body of [TI-funded] studies that has been
published already and that are in the publishing process’ as ‘fundamental’ for business transforma-
tion (Int18). According to TI executives, the science is ‘extremely high quality’ ‘because it faces very,
very, robust scrutiny and it’s done with very high quality labs, very high quality methodology and
it’s published in good quality journals that are not speciﬁcally on tobacco’ (Int25). BAT has ‘a new
scientiﬁc framework to assess the reduced-risk potential of nicotine and new tobacco products’
being developed using a ‘four-stage process’ (Hedley, 2015). Similarly, ‘PMI Science’ has been
established to ‘conduct rigorous and scientiﬁc assessment to demonstrate that [ANDS] reduce
risk and comply with emerging standards’ (https://www.pmiscience.com). This was described by TI
representatives as ‘a paradigm shift for our industry’ as ‘no one’s had these types of products
before and certainly not with the level of scientiﬁc substantiation and evidence which [the TI is]
compiling’ (Int18). As a TI spokesperson explained, ‘the one thing that we have, and it’s a business
strategy, is that we steward these products substantially’ (Int4).
This stewardship provides a fourth opportunity: a route into regulation. TI respondents said that it is
now possible to work with ‘the regulators . . . and enlighten them of the risks’ (Int11) with ‘millions of
pages of high quality scientiﬁc research’ (Int18). One TI executive further explained this business strategy:
This is where we would like to . . . work with . . . public health, with regulators who have an interest in reduced
risk . . . to ﬁnd out what is the appropriate regulatory path . . . So we are investing a huge amount of time,
resource, expertise, in the science to enable those conversations and to objectively look at the best route
forward. (Int18)
They added that studies are being conducted ‘to demonstrate that they [ANDS] reduce risk’, and
these ﬁndings will ‘become a corner-stone’ of regulatory applications (Int18). While costly, ‘shaping
future regulation’ in this way, as BAT expressed it, is vital (Wheaton, 2015). As a TI spokesperson
explained, regulation plays ‘a very outsized role in . . . the market’ as it ‘governs the rules’ of how
the TI ‘can market their products and what types of products and what goes into products’ (Int9).
The focus, according to independent and TI respondents, is still on proﬁtability. One TI interviewee
reﬂected on how tobacco ‘companies are amoral. They’re not immoral. They’re not moral. And if
they’re behaving in a moral way, it’s because they believe that’s gonna advance their business
interests’, so ‘the health beneﬁts are a pleasant but a, kind of. . . accident, if you will’ (Int2). A diﬀerent
TI spokesperson added that while there is an ‘element of “we have to do what’s the right thing to
do” . . . you can’t do that at the expense of shareholders’ as you’re ‘running a commercial business’
(Int7). The same proviso applies when BAT’s MD of next-generation products speaks of a ‘win-win-
win situation – a win for society as public health aims are advanced, a win for consumers as exciting
new products become available and a win for share-holders as sustainable value is generated’
(Tuinstra, 2015, p. 24). So, contributing to public health, or appearing to do so, becomes part of
the business strategy. TI industry responses to the Scottish Government’s Consultation on e-cigar-
ettes in 2014/2015 exemplify this strategic approach (see Appendix 2 in Supplement).
Finally, ANDS oﬀer the opportunity to rebuild corporate reputations and guard against litigation.
Openness, particularly about risks and addiction, with both stakeholders and the public, is now a key
strategy. TI respondents spoke about how the industry has ‘opened up’ ‘the information ﬂow into their
R&D process’ (Int9) and are now ‘openly talk[ing] about the amount of money that we [they] invest
every year in R&D into the products’ (Int4). Public health was encouraged to look at R&D expenditures
to see the increases. Similarly, according to TI executives, companies want consumers to ‘be aware of
the risks’ (Int11) and ‘are encouraging retailers to educate staﬀ to be able to deal with the increasingly
complex shopper requirements’ (Hegarty, 2015, p. 52). This frankness, according to a TI representative,
will bring reputational beneﬁts: ‘if you’re allowed to actually start communicating about risk in a proper
way, I think that will lead to a shift [in company standing]’ (Int6).
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BAT, for example, wants ‘to lead the segment’ by oﬀering consumers ‘a choice of products
across the risk continuum, including vapor, tobacco-heating and licensed medicinal products’
(Tuinstra, 2015, p. 24). In this way, the decisions about risk are delegated to the consumer, making
litigation less likely.
Threats
Now, the TI is established in the ANDS market, the principle threats come from two sets of
competitors: other tobacco companies and independent operators. The former is nothing new as
the tobacco multinationals were ﬁerce rivals long before ANDS emerged.
The threat from the independents, however, is novel and relates to product characteristics. As
one independent explained, for the tobacco companies, the cig-a-like ‘in many respects is the
perfect product’ because it is easily mass produced, has ‘low inventory [and] next to no shelving
cost’, and is ‘very, very high on margin’ (Int3). It also enables them to exploit their formidable
distribution networks. The trouble is ‘it’s just not perfect for the consumer’ (Int3). A TI executive
agreed that cig-a-likes are ‘pretty ineﬀective in terms of giving smokers what they want’ (Int4).
Independents explained that users prefer the more ﬂexible option of buying one ‘bit of hardware’
or tank which they can reﬁll with ‘somebody else’s liquid that you fancy – and there are thousands’
(Int5). While some companies are happy to operate on this small-scale bespoke basis, for a big player,
‘there’s no long-term big commercial market in e-liquids. It’s a commodity product’ (Int5).
Furthermore, ‘there’s no barrier to entry into that market’ (Int5), threatening the current market
dominance of the big ﬁve tobacco companies. The ‘Apple model’, according to independents, may
provide a way out here: the TI is working on tank systems which tie customers into using only their
reﬁlls and components, as happens with the iPhone ‘because that’s a viable business model’ (Int5).
There is now an ‘emerging sub-category of closed capsule tank products which tobacco companies
in particular are making central to their e-cigarette product pipelines’ (MacGuill, 2015).
Discussion
The results are presented from the perspective of the respondents, all of whom are closely involved
with the tobacco and ANDSmarkets, and so need to be interpreted with caution. It is also important to
note that the TI is not amonolith. It comprises a number ofmultinationals who are in ﬁerce competition
with one another and the recently arrived independents, and this makes generalisation hazardous.
Nonetheless, it does seem clear that after the initial shock created by the unexpected arrival of
e-cigarettes and ANDS, which at one point might have represented an existential threat to their
existence, the tobacco multinationals are doing all they can to turn this potential menace into
a range of business opportunities. Interviewees argued that the new arrivals play to their strengths,
especially their customer links; expertise in nicotine; and, thanks to combustibles, massive ﬁnancial
resources. This, it was claimed, has enabled them to create multiple opportunities. Speciﬁcally, they
have been able to diversify into broader product portfolios in which combustible and alternative
products can comfortably coexist, set new long-term strategic goals, develop scientiﬁc and even
regulatory capacity, and to possibly retrieve their corporate reputations by seeming to align with
public health objectives. By the same token, ANDS, the interviews suggested, have the potential to
reduce the TI’s existing weaknesses, especially its poor standing among both consumers and stake-
holders. The principal threat for the major tobacco players comes from the independent sector, which
is prepared and able to satisfy a bespoke set of consumer needs. Themultinationals by contrast need to
turn ANDS into a genuinely mass-market product, which appeals to its global customer base. They are
making progress on this and, given the continued buoyancy of the combustibles market, have
extensive resources at their disposal to continue the eﬀort.
The study has limitations. Qualitative methods make generalisation diﬃcult and resources
inevitably constrained data collection. Furthermore, it measures reported not actual behaviour,
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and so, as with public surveys, there may be a tendency on the part of interviewees to over-
rationalise, on one hand, and understate contradictions, on the other hand. However, as the ﬁrst
empirical investigation with business stakeholders since the advent of ANDS, it gives unique
insights into how a market which has such immense implications for public health may develop.
Conclusion
The public health literature is replete with warnings about the duplicity and malevolence of ‘Big
Tobacco’. That is why Article 5.3 of the WHO FCTC explicitly protects tobacco control policies from
the ‘commercial and other vested interests of the tobacco industry’. Over 180 countries have now
signed up to the treaty, covering 90% of humanity (WHO, 2018).
As Bell (2013, p. 38) notes, however, this can constrain critical thinking:
over the past two decades tobacco studies scholars have had to exercise increasing care in how they frame
their research and those whose tone is critical of mainstream tobacco control open themselves up to
accusations of alignment with ‘pro-tobacco interests’.
These tensions have been exacerbated by the arrival of ANDS, the pros and cons of which can
lead to peer review pressures and are diﬃcult to discuss without being accused of uncritically
accepting TI public relations (de Andrade et al., 2017; Lucherini, 2018). The diﬃculty of maintaining
a neutral position on such a divisive and controversial topic became apparent during our own
review process, which highlighted the need to attend suﬃciently to the social and public health
costs of corporate political activity (Ulucanlar, Fooks, & Gilmore, 2016).
At the heart of this confusion and disruption is the product itself. Many – if not most – in public
health would agree that ANDS are signiﬁcantly less harmful than combustibles. This has never
happened before. ANDS, which include products produced by the TI, are now being actively
recommended both by UK government health services (NHS, 2018) and Europe’s biggest cancer
charity (Cancer Research UK, 2017) to help people stop smoking. The TI meanwhile is enjoying
a gamut of new business opportunities. It can now diversify in a way that it has been unable to do
in its 150-year existence. It can plan long-term beyond the impasse of a lethal product and is even
able to contemplate reintroduction to the respectable business community.
Yet, as for any corporation, the ﬁduciary imperative remains. The TI, whatever the improvements
in its products, will always prioritise decisions on the basis of proﬁtability and corporate growth
(Branston & Sweanor, 2015). From a critical public health perspective, the concern here is that the
interests of the investors will always be preferred if the ‘win-win-win’ for society, customers, and
shareholders hits problems. As both independent and TI respondents noted in our study, proﬁts
are the arbiter of success, and any health or social beneﬁts are accidental.
The independent sector is not dominated by corporations, but, nonetheless, market imperatives
apply. So, while health and social beneﬁts are, for some companies at least, core business strategies
and these can drive innovation in the vaping sector, commercial sustainability also depends on
ﬁnancial outcomes. At the time of writing, the independent product Juul was dominating the mass-
manufactured e-cigarette market, holding more than 70% of US sales, and ahead of ANDS oﬀerings
from Big Tobacco (analyst, personal communication, 27 July 2018). This, amid concerns of Juul’s
youth appeal and use (Halliwell & Saker-Clark, 2018).
It remains to be seen whether this product speciﬁcally, or disruptive technology in this space, will
‘lead to more than changes in industries and consumer behaviour’ and genuinely challenge ‘existing
power relationships and established wisdom’ (Stimson, Thom, & Costall, 2014, p. 654). Alternatively,
perhaps, it is just a matter of time before one of the big players will acquire the ‘nascent interloper’
(Int13) as has happened in the past (Bauld et al., 2016). Tobacco companies certainly have themeans to
take over competitors when threatened. The Marlboro brand alone was valued at US$24.1 billion in
2017 (Forbes, 2018). However, Juul was recently valued at US$15 billion just three years after arriving on
the market which suggests that it could be ﬁnancially self-suﬃcient in relation to investment or
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acquisition from major tobacco players (Financial Times, 2018). It is worth noting though that the
global cigarette industry was valued at more than US$683 billion in 2016 compared to the global
e-cigarette market which was worth US$11.92 billion (Campaign for Tobacco Free Kids, 2017;
TechNavio, 2016), although this is expected to reach US$48 billion by 2023 (PRNewswire, 2018).
Disruptive innovations are not unique to tobacco control. Equivalent technological solu-
tions – with concomitant business opportunities − are emerging in the obesity and alcohol
ﬁelds (Crino, Sacks, Vandevijvere, Swinburn, & Neal, 2015), and there are those in public
health who welcome these moves (Derricott, 2015). Arguably, also, it is a predictable devel-
opment in our liberalised market system, where consumption is the route to contentment,
and every problem becomes a potential new product or service development opportunity.
When problems arise which cannot be solved by consumption, however, the market ﬁnds it
much more diﬃcult to respond. Climate change is the obvious and pressing example here. As
climate scientist Stephen Emmott explains, ‘we need to consume less. A lot less. Less food, less
energy, less stuﬀ. Fewer cars, electric cars, cotton T-shirts, laptops, mobile phone upgrades. Far
fewer’ (Emmott, 2013, p. 184). Such shrinkage is anathema to corporate capitalism (Jackson, 2009).
Thus, the problems we face are not just those of a few aberrant markets, such as tobacco, alcohol or
unhealthy food, or the occasional misbehaving corporation, but of an economic system that is
predicated on ever-increasing consumption and perpetual growth. This is at odds with the reality of
a ﬁnite planet and suggests that, rather than just looking to the market for potential solutions, such as
e-cigarettes, there is also a need to critique its failings and seek ‘coherent alternative[s]’ (Fisher, 2009).
Note
1. During the review process for this paper, PMI announced plans to go ‘tobacco-free’ and established
a US$1 billion foundation for a smoke-free world. See https://www.pmi.com/who-we-are/designing-a-smoke-
free-future.
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